DarioHealth (DRIO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

DRIO Stock Forecast

DarioHealth stock forecast is as follows: an average price target of $10.75 (represents a 1243.75% upside from DRIO’s last price of $0.80) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

DRIO Price Target

The average price target for DarioHealth (DRIO) is $10.75 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $7.50. This represents a potential 1243.75% upside from DRIO's last price of $0.80.

DRIO Analyst Ratings

Buy

According to 3 Wall Street analysts, DarioHealth's rating consensus is 'Buy'. The analyst rating breakdown for DRIO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

DarioHealth Price Target by Analyst

Date	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 16, 2022	Industrial Alliance Securities	$7.50	$5.18	44.79%	837.50%
Aug 18, 2022	Cowen & Co.	$14.00	$5.49	155.01%	1650.00%
May 16, 2022	Cowen & Co.	$18.00	$6.33	184.36%	2150.00%

The latest DarioHealth stock forecast, released on Nov 16, 2022 by Industrial Alliance Securities company, set a price target of $7.50, which represents a 44.79% increase from the stock price at the time of the forecast ($5.18), and a 837.50% increase from DRIO last price ($0.80).

DarioHealth Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.80	$0.80	$0.80
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of DarioHealth stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DarioHealth's last price of $0.80. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 14, 2024	Cowen & Co.	Buy	Buy	Hold
Nov 16, 2022	Alliance Global Partners	Buy	Buy	Hold
Aug 18, 2022	Aegis Capital	Buy	Buy	Hold
Aug 18, 2022	Cowen & Co.	Outperform	Outperform	Hold
May 16, 2022	Aegis Capital	Buy	Buy	Hold
May 16, 2022	Cowen & Co.	Outperform	Outperform	Hold
May 13, 2022	Alliance Global Partners		Buy	Upgrade

DarioHealth's last stock rating was published by Cowen & Co. on Jun 14, 2024. The company gave DRIO a "Buy" rating, the same as its previous rate.

DarioHealth Financial Forecast

DarioHealth Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$3.62M	$3.52M	$6.15M	$7.07M	$6.81M	$6.61M	$6.18M	$8.06M	-	$1.21M	$5.26M	$3.60M	$2.08M	$2.04M	$1.79M	$1.67M	$1.80M	$1.87M
Avg Forecast	$13.42M	$12.73M	$12.18M	$11.74M	$11.65M	$9.79M	$8.72M	$8.14M	$7.41M	$7.40M	$7.92M	$6.76M	$3.78M	$5.42M	$6.50M	$6.70M	$6.71M	$6.29M	$8.25M	$6.82M	$6.02M	$5.77M	$5.14M	$4.00M	$2.11M	$1.95M	$1.55M	$1.75M	$2.05M	$1.93M
High Forecast	$13.43M	$12.74M	$12.19M	$11.75M	$11.66M	$9.80M	$8.73M	$8.15M	$7.42M	$7.40M	$7.92M	$6.76M	$3.78M	$5.42M	$6.50M	$6.71M	$6.72M	$6.29M	$8.25M	$6.82M	$6.02M	$5.77M	$5.14M	$4.00M	$2.11M	$1.95M	$1.55M	$1.75M	$2.05M	$1.93M
Low Forecast	$13.41M	$12.72M	$12.17M	$11.73M	$11.65M	$9.79M	$8.72M	$8.14M	$7.41M	$7.39M	$7.91M	$6.75M	$3.78M	$5.42M	$6.49M	$6.70M	$6.71M	$6.29M	$8.25M	$6.82M	$6.02M	$5.77M	$5.14M	$4.00M	$2.11M	$1.95M	$1.55M	$1.75M	$2.05M	$1.93M
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.96%	0.65%	0.95%	1.05%	1.01%	1.05%	0.75%	1.18%	-	0.21%	1.02%	0.90%	0.99%	1.05%	1.15%	0.95%	0.88%	0.97%

DarioHealth's average Quarter revenue forecast for Mar 24 based on 1 analysts is $6.76M, with a low forecast of $6.75M, and a high forecast of $6.76M. DRIO's average Quarter revenue forecast represents a 86.92% increase compared to the company's last Quarter revenue of $3.62M (Dec 23).

DarioHealth EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-12.76M	$-15.55M	$-14.02M	$-10.91M	$-7.51M	$-13.35M	$-16.15M	$-14.82M	$-21.66M	$2.60M	$-16.96M	$-14.53M	$-8.95M	$-6.50M	$-3.96M	$-9.85M	$-4.29M	$-2.73M
Avg Forecast	$-13.42M	$-12.73M	$-12.18M	$-11.74M	$-11.65M	$-9.79M	$-8.72M	$-8.14M	$-7.41M	$-7.40M	$-7.92M	$-6.76M	$-3.78M	$-5.42M	$-6.50M	$-6.70M	$-6.71M	$-6.29M	$-8.25M	$-18.32M	$-6.02M	$-5.77M	$-5.14M	$-16.20M	$-2.11M	$-1.95M	$-1.55M	$-7.06M	$-2.05M	$-1.93M
High Forecast	$-13.41M	$-12.72M	$-12.17M	$-11.73M	$-11.65M	$-9.79M	$-8.72M	$-8.14M	$-7.41M	$-7.39M	$-7.91M	$-6.75M	$-3.78M	$-5.42M	$-6.49M	$-6.70M	$-6.71M	$-6.29M	$-8.25M	$-14.66M	$-6.02M	$-5.77M	$-5.14M	$-12.96M	$-2.11M	$-1.95M	$-1.55M	$-5.65M	$-2.05M	$-1.93M
Low Forecast	$-13.43M	$-12.74M	$-12.19M	$-11.75M	$-11.66M	$-9.80M	$-8.73M	$-8.15M	$-7.42M	$-7.40M	$-7.92M	$-6.76M	$-3.78M	$-5.42M	$-6.50M	$-6.71M	$-6.72M	$-6.29M	$-8.25M	$-21.98M	$-6.02M	$-5.77M	$-5.14M	$-19.44M	$-2.11M	$-1.95M	$-1.55M	$-8.48M	$-2.05M	$-1.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	3.37%	2.87%	2.16%	1.63%	1.12%	2.12%	1.96%	0.81%	3.60%	-0.45%	3.30%	0.90%	4.25%	3.33%	2.55%	1.39%	2.09%	1.41%

1 analysts predict DRIO's average Quarter EBITDA for Dec 21 to be $-6.02M, with a high of $-6.02M and a low of $-6.02M. This is -331.57% lower than DarioHealth's previous annual EBITDA (Sep 21) of $2.60M.

DarioHealth Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-12.00M	$16.90M	$18.28M	$12.41M	$-12.62M	$-16.69M	$-18.03M	$-15.96M	$32.73M	-	$-17.77M	$-14.97M	$-9.00M	$-6.55M	$-4.01M	$-9.89M	$-4.17M	$-2.81M
Avg Forecast	$-5.25M	$-5.25M	$-5.66M	$-5.66M	$-5.66M	$-7.28M	$-8.08M	$-8.49M	$-13.34M	$-8.76M	$-17.99M	$-11.92M	$-15.76M	$-21.02M	$-20.77M	$-20.13M	$-24.65M	$-30.39M	$-30.04M	$-19.56M	$-46.09M	$-39.32M	$-34.60M	$-16.69M	$-34.19M	$-27.22M	$-55.66M	$-7.10M	$-40.63M	$-71.70M
High Forecast	$-5.25M	$-5.25M	$-5.65M	$-5.65M	$-5.65M	$-7.27M	$-8.08M	$-8.48M	$-13.33M	$-8.75M	$-17.97M	$-11.91M	$-15.75M	$-21.00M	$-20.76M	$-20.11M	$-24.63M	$-30.39M	$-30.04M	$-15.65M	$-46.09M	$-39.32M	$-34.60M	$-13.35M	$-34.19M	$-27.22M	$-55.66M	$-5.68M	$-40.63M	$-71.70M
Low Forecast	$-5.26M	$-5.26M	$-5.66M	$-5.66M	$-5.66M	$-7.28M	$-8.09M	$-8.50M	$-13.35M	$-8.77M	$-18.00M	$-11.93M	$-15.78M	$-21.04M	$-20.79M	$-20.15M	$-24.68M	$-30.39M	$-30.04M	$-23.48M	$-46.09M	$-39.32M	$-34.60M	$-20.03M	$-34.19M	$-27.22M	$-55.66M	$-8.51M	$-40.63M	$-71.70M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.76%	-0.80%	-0.88%	-0.62%	0.51%	0.55%	0.60%	0.82%	-0.71%	-	0.51%	0.90%	0.26%	0.24%	0.07%	1.39%	0.10%	0.04%

DarioHealth's average Quarter net income forecast for Dec 23 is $-15.76M, with a range of $-15.78M to $-15.75M. DRIO's average Quarter net income forecast represents a -193.25% decrease compared to the company's last Quarter net income of $16.90M (Sep 23).

DarioHealth SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$10.02M	$10.49M	$10.87M	$10.41M	$6.96M	$11.57M	$14.36M	$13.93M	-	$17.82M	$15.77M	$12.75M	$8.19M	$6.20M	$3.93M	$9.66M	$4.18M	$2.81M
Avg Forecast	$34.14M	$32.39M	$30.98M	$29.86M	$29.65M	$24.91M	$22.19M	$20.72M	$18.85M	$18.82M	$20.14M	$17.20M	$9.62M	$13.79M	$16.53M	$17.06M	$17.08M	$16.01M	$20.99M	$17.35M	$15.31M	$14.69M	$13.09M	$10.17M	$5.36M	$4.97M	$3.96M	$4.45M	$5.22M	$4.92M
High Forecast	$34.16M	$32.42M	$31.01M	$29.89M	$29.67M	$24.93M	$22.21M	$20.73M	$18.87M	$18.83M	$20.15M	$17.21M	$9.63M	$13.80M	$16.54M	$17.07M	$17.09M	$16.01M	$20.99M	$17.35M	$15.31M	$14.69M	$13.09M	$10.17M	$5.36M	$4.97M	$3.96M	$4.45M	$5.22M	$4.92M
Low Forecast	$34.12M	$32.37M	$30.96M	$29.85M	$29.63M	$24.90M	$22.18M	$20.71M	$18.84M	$18.81M	$20.13M	$17.18M	$9.61M	$13.78M	$16.52M	$17.05M	$17.07M	$16.01M	$20.99M	$17.35M	$15.31M	$14.69M	$13.09M	$10.17M	$5.36M	$4.97M	$3.96M	$4.45M	$5.22M	$4.92M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.04%	0.76%	0.66%	0.61%	0.41%	0.72%	0.68%	0.80%	-	1.21%	1.20%	1.25%	1.53%	1.25%	0.99%	2.17%	0.80%	0.57%

DarioHealth's average Quarter SG&A projection for Mar 24 is $17.20M, based on 1 Wall Street analysts, with a range of $17.18M to $17.21M. The forecast indicates a 71.56% rise compared to DRIO last annual SG&A of $10.02M (Dec 23).

DarioHealth EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.44	$0.49	$0.58	$0.45	$-0.53	$-0.73	$-0.80	$-0.81	$2.09	$-1.18	$-0.99	$-0.92	$-1.23	$-0.71	$-0.68	$-1.57	$-1.35	$-1.20
Avg Forecast	$-0.13	$-0.13	$-0.14	$-0.14	$-0.14	$-0.18	$-0.20	$-0.21	$-0.33	$-0.22	$-0.45	$-0.29	$-0.39	$-0.52	$-0.51	$-0.50	$-0.61	$-0.76	$-0.75	$-0.96	$-1.16	$-0.99	$-0.87	$-0.80	$-0.86	$-0.68	$-1.40	$-0.75	$-1.02	$-1.80
High Forecast	$-0.13	$-0.13	$-0.14	$-0.14	$-0.14	$-0.18	$-0.20	$-0.21	$-0.33	$-0.22	$-0.44	$-0.29	$-0.39	$-0.52	$-0.51	$-0.50	$-0.61	$-0.76	$-0.75	$-0.96	$-1.16	$-0.99	$-0.87	$-0.80	$-0.86	$-0.68	$-1.40	$-0.75	$-1.02	$-1.80
Low Forecast	$-0.13	$-0.13	$-0.14	$-0.14	$-0.14	$-0.18	$-0.20	$-0.21	$-0.33	$-0.22	$-0.45	$-0.30	$-0.39	$-0.52	$-0.51	$-0.50	$-0.61	$-0.76	$-0.75	$-0.96	$-1.16	$-0.99	$-0.87	$-0.80	$-0.86	$-0.68	$-1.40	$-0.75	$-1.02	$-1.80
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.13%	-0.94%	-1.13%	-0.90%	0.87%	0.96%	1.06%	0.85%	-1.81%	1.20%	1.14%	1.16%	1.43%	1.04%	0.49%	2.09%	1.32%	0.67%

According to 1 Wall Street analysts, DarioHealth's projected average Quarter EPS for Dec 23 is $-0.39, with a low estimate of $-0.39 and a high estimate of $-0.39. This represents a -179.59% decrease compared to DRIO previous annual EPS of $0.49 (Sep 23).

DarioHealth Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DRIO	DarioHealth	$0.71	$10.75	1414.08%	Buy
STIM	Neuronetics	$1.30	$8.00	515.38%	Buy
BDSX	Biodesix	$1.39	$3.00	115.83%	Buy
XGN	Exagen	$5.80	$5.00	-13.79%	Buy

DRIO Forecast FAQ

Is DarioHealth a good buy?

Yes, according to 3 Wall Street analysts, DarioHealth (DRIO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of DRIO's total ratings.

What is DRIO's price target?

DarioHealth (DRIO) average price target is $10.75 with a range of $7.5 to $14, implying a 1243.75% from its last price of $0.8. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will DarioHealth stock go up soon?

According to Wall Street analysts' prediction for DRIO stock, the company can go up by 1243.75% (from the last price of $0.8 to the average price target of $10.75), up by 1650.00% based on the highest stock price target, and up by 837.50% based on the lowest stock price target.

Can DarioHealth stock reach $1?

DRIO's average twelve months analyst stock price target of $10.75 supports the claim that DarioHealth can reach $1 in the near future.

What are DarioHealth's analysts' financial forecasts?

DarioHealth's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $38.31M (high $38.34M, low $38.29M), average EBITDA is $-38.311M (high $-38.286M, low $-38.338M), average net income is $-29.505M (high $-29.48M, low $-29.532M), average SG&A $97.47M (high $97.53M, low $97.4M), and average EPS is $-0.73 (high $-0.729, low $-0.731). DRIO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $50.07M (high $50.11M, low $50.04M), average EBITDA is $-50.07M (high $-50.038M, low $-50.105M), average net income is $-21.825M (high $-21.807M, low $-21.846M), average SG&A $127.38M (high $127.47M, low $127.3M), and average EPS is $-0.54 (high $-0.54, low $-0.54).

Did the DRIO's actual financial results beat the analysts' financial forecasts?

Based on DarioHealth's last annual report (Dec 2023), the company's revenue was $20.35M, which missed the average analysts forecast of $22.4M by -9.16%. Apple's EBITDA was $-56.189M, beating the average prediction of $-22.405M by 150.79%. The company's net income was $63.51M, missing the average estimation of $-77.682M by -181.76%. Apple's SG&A was $41.92M, missing the average forecast of $57M by -26.45%. Lastly, the company's EPS was $1.93, missing the average prediction of $-1.922 by -200.42%. In terms of the last quarterly report (Dec 2023), DarioHealth's revenue was $3.62M, missing the average analysts' forecast of $3.78M by -4.36%. The company's EBITDA was $-12.756M, beating the average prediction of $-3.781M by 237.37%. DarioHealth's net income was $-12.001M, missing the average estimation of $-15.763M by -23.87%. The company's SG&A was $10.02M, beating the average forecast of $9.62M by 4.20%. Lastly, the company's EPS was $-0.44, beating the average prediction of $-0.39 by 12.82%